Core Viewpoint - NYO3 has launched its "Anti-Aging Trio" series in Shanghai, focusing on scientific anti-aging solutions for various consumer needs, including skin and ovarian health [1][3]. Group 1: Product Overview - The "Anti-Aging Trio" includes three key products: Ageless Deep Sea Collagen Peptide, Ageless Skin Care Pills, and Ageless Noble Nest Pills, each targeting specific anti-aging needs [3]. - Ageless Deep Sea Collagen Peptide has increased its collagen tripeptide content from 5500mg to 6100mg, achieving three times the market standard, with a low caloric value of 31.3 kcal per bottle [3]. - Ageless Skin Care Pills utilize a phospholipid cell-level delivery technology, achieving a 98% absorption rate, with clinical trials showing significant improvements in skin texture and appearance over 28 days [3][9]. - Ageless Noble Nest Pills combine phospholipid Omega-3 and inositol to enhance endocrine regulation and ovarian cell energy activation [3]. Group 2: Technological Leadership - NYO3 leverages advanced Norwegian anti-aging research and collaborates with the NO-AGE research center to develop high-end oral anti-aging products [5]. - The company emphasizes technological innovation as its core competitive advantage, utilizing a unique phospholipid delivery system to enhance absorption rates to 98% [5]. - Ageless products promise visible results within 30 days, addressing common consumer concerns about high costs and slow effects in the oral anti-aging market [5]. Group 3: Market Recognition - NYO3 has gained recognition as the "No. 1 Anti-Aging Brand in Northern Europe," supported by clinical data from NO-AGE and real-world testing conducted in collaboration with a reputable testing agency [7]. - The Ageless product line has achieved significant market success, with the Skin Care Pills topping the Tmall International oral beauty rankings shortly after launch [9]. - The brand's commitment to quality and innovation has earned it accolades, including the prestigious Monte Award in the dietary nutrition sector [9].